SG11201402405QA - Muscarinic m1 receptor agonists - Google Patents
Muscarinic m1 receptor agonistsInfo
- Publication number
- SG11201402405QA SG11201402405QA SG11201402405QA SG11201402405QA SG11201402405QA SG 11201402405Q A SG11201402405Q A SG 11201402405QA SG 11201402405Q A SG11201402405Q A SG 11201402405QA SG 11201402405Q A SG11201402405Q A SG 11201402405QA SG 11201402405Q A SG11201402405Q A SG 11201402405QA
- Authority
- SG
- Singapore
- Prior art keywords
- muscarinic
- receptor agonists
- agonists
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161632813P | 2011-11-18 | 2011-11-18 | |
| PCT/GB2012/052857 WO2013072705A1 (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402405QA true SG11201402405QA (en) | 2014-09-26 |
Family
ID=47278335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402405QA SG11201402405QA (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US9187451B2 (en) |
| EP (1) | EP2780015B1 (en) |
| JP (2) | JP6083818B2 (en) |
| CN (2) | CN104039321B (en) |
| AU (3) | AU2012338581B2 (en) |
| BR (1) | BR112014012056B1 (en) |
| CA (1) | CA2856076C (en) |
| DK (1) | DK2780015T3 (en) |
| ES (1) | ES2619829T3 (en) |
| GB (1) | GB2511685A (en) |
| HK (1) | HK1201737A1 (en) |
| HU (1) | HUE033114T2 (en) |
| IN (1) | IN2014KN01075A (en) |
| PL (1) | PL2780015T3 (en) |
| PT (1) | PT2780015T (en) |
| SG (1) | SG11201402405QA (en) |
| WO (1) | WO2013072705A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104039321B (en) | 2011-11-18 | 2017-02-22 | 赫普泰雅治疗有限公司 | Muscarinic m1 receptor agonists |
| DK2897948T3 (en) | 2012-09-18 | 2016-12-05 | Heptares Therapeutics Ltd | BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS |
| GB2519470A (en) * | 2013-09-18 | 2015-04-22 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic M1 receptor agonists |
| EP3406609A1 (en) * | 2014-02-06 | 2018-11-28 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic receptor agonists |
| GB201404922D0 (en) * | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201519352D0 (en) * | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| CN108226319A (en) * | 2016-12-22 | 2018-06-29 | 亚宝药业集团股份有限公司 | A kind of method for detecting optical isomer in Rivastigmine patch |
| TW201922758A (en) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | Enamines and diastereo-selective reduction of enamines |
| JP6691928B2 (en) * | 2018-02-07 | 2020-05-13 | 株式会社ジンズホールディングス | Eyewear set and signal processing unit |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN113121495A (en) * | 2020-01-10 | 2021-07-16 | 深圳市九明药业有限公司 | Preparation method of desloratadine |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56110674A (en) | 1980-01-24 | 1981-09-01 | Janssen Pharmaceutica Nv | Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative |
| US4369184A (en) | 1980-01-24 | 1983-01-18 | Janssen Pharmaceutica N.V. | 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US5446051A (en) | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
| AU701127B2 (en) | 1994-10-27 | 1999-01-21 | Merck & Co., Inc. | Muscarine antagonists |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| WO1997016187A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| US5854245A (en) * | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| AU3632297A (en) | 1996-08-26 | 1998-03-19 | Pfizer Inc. | Spirocyclic dopamine receptor subtype ligands |
| WO1998057641A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
| GB9715892D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| AU2095099A (en) * | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists |
| WO1999032486A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| AU2206699A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| AU2307999A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| CZ286152B6 (en) | 1998-03-13 | 2000-01-12 | Miroslav Ing. Csc. Vlček | Transparent and semitransparent diffraction elements, particularly holograms and process of their production |
| ID26399A (en) * | 1998-04-28 | 2000-12-21 | Dainippon Pharmaceutical Co | DEGREE 1- (1-SUBSTITUTED-4-PIPERIDINYL) METHYL-4-PIPERIDIN, THE PROCESS OF MAKING, PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPOUNDS, AND THEIR INTERMEDIETY |
| KR100439357B1 (en) | 1999-05-04 | 2004-07-07 | 쉐링 코포레이션 | Piperidine derivatives useful as CCR5 antagonists |
| HUP0202734A3 (en) | 1999-05-04 | 2003-11-28 | Schering Corp | Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| DK1218372T3 (en) | 1999-09-13 | 2003-10-20 | Boehringer Ingelheim Pharma | Novel heterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| WO2001027104A1 (en) | 1999-10-13 | 2001-04-19 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| EP1379506A2 (en) * | 2000-11-28 | 2004-01-14 | Eli Lilly And Company | Substituted carboxamides |
| WO2002085890A1 (en) | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| GB0128378D0 (en) | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
| US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| IL162616A0 (en) | 2001-12-28 | 2005-11-20 | Acadia Pharm Inc | Tetrahydroquinoline analogues as muscarinic agonists |
| US7256186B2 (en) | 2002-02-06 | 2007-08-14 | Schering Corporation | Gamma secretase inhibitors |
| US20040171614A1 (en) | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
| IL163923A0 (en) * | 2002-03-28 | 2005-12-18 | Tanabe Seiyaku Co | Benzofuran derivatives |
| EP1552842A1 (en) | 2002-06-07 | 2005-07-13 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| ATE396969T1 (en) | 2002-07-31 | 2008-06-15 | Ranbaxy Lab Ltd | 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)HEXANE DERIVATIVES THAT ARE SUITABLE AS MUSCARINE RECEPTOR ANTAGONISTS |
| KR20050062575A (en) | 2002-09-30 | 2005-06-23 | 뉴로서치 에이/에스 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use |
| NZ539952A (en) | 2002-11-22 | 2008-05-30 | Japan Tobacco Inc | Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X |
| EP2431357A3 (en) | 2002-11-27 | 2012-08-22 | Incyte Corporation | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors |
| WO2004069828A1 (en) | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | Piperidine compound and medicinal use thereof |
| CA2529686C (en) | 2003-07-17 | 2010-06-15 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
| JPWO2005037269A1 (en) | 2003-10-21 | 2006-12-28 | 住友製薬株式会社 | Novel piperidine derivatives |
| EP1725235B1 (en) | 2004-02-05 | 2009-04-15 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
| RU2006132465A (en) | 2004-02-10 | 2008-03-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | CCR5 CHEMOKIN RECEPTOR MODULATORS |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| JP2008521821A (en) | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | Muscarinic receptor modulators |
| JP4774995B2 (en) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | Pharmaceutical composition comprising an acylaminothiazole derivative as an active ingredient |
| US7786308B2 (en) | 2005-03-28 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
| EP2468743A1 (en) | 2005-06-24 | 2012-06-27 | Toyama Chemical Co., Ltd. | Nitrogen-containing bicyclic compounds useful as antibacterial agents |
| JP2009521483A (en) * | 2005-12-22 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | Muscarinic receptor modulators |
| JP5512975B2 (en) | 2005-12-29 | 2014-06-04 | アッヴィ・インコーポレイテッド | Protein kinase inhibitors |
| US8003660B2 (en) | 2006-02-22 | 2011-08-23 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| JP2009527569A (en) | 2006-02-22 | 2009-07-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | Modulator of muscarinic receptor |
| CN101553231A (en) | 2006-08-15 | 2009-10-07 | 弗特克斯药品有限公司 | Modulators of muscarinic receptors |
| CA2673375A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | 1-aminomethyl-l-phenyl-cyclohexane derivatives as ddp-iv inhibitors |
| WO2008117229A1 (en) | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| UY31672A1 (en) * | 2008-02-28 | 2009-09-30 | "MUSCARINIC RECEPTORS AGONISTS PHARMACEUTICAL COMPOSITIONS METHODS OF TREATMENT OF THE SAME, AND PROCEDURES FOR THEIR PREPARATION" | |
| WO2009118370A1 (en) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| EP2344457A1 (en) | 2008-10-29 | 2011-07-20 | Grünenthal GmbH | Substituted spiroamines |
| EP2379525B1 (en) * | 2008-12-19 | 2015-07-29 | Boehringer Ingelheim International GmbH | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
| US20100267689A1 (en) | 2009-04-17 | 2010-10-21 | Xuqing Zhang | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| FR2945531A1 (en) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | 7-AZA-SPIRO® 3,5-NONANE-7-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| US20130197027A1 (en) | 2010-03-10 | 2013-08-01 | Craig Lindsley | Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same |
| EP2560962B1 (en) | 2010-04-22 | 2015-05-20 | Janssen Pharmaceutica NV | Indazole compounds useful as ketohexokinase inhibitors |
| EP2563127A4 (en) | 2010-04-27 | 2013-11-06 | Merck Sharp & Dohme | Prolylcarboxypeptidase inhibitors |
| WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| WO2011150183A1 (en) | 2010-05-28 | 2011-12-01 | Ge Healthcare Limited | Radiolabeled compounds and methods thereof |
| BR112013006344A2 (en) | 2010-09-17 | 2016-06-21 | Array Biopharma Inc | piperdinyl substituted lactams as gpr119 modulators, pharmaceutical composition comprising them, use and process for preparing same |
| WO2012125661A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists |
| JP2013010719A (en) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | Benzimidazolone and oxindole derivative, and pharmaceutical application of them |
| CN104039321B (en) | 2011-11-18 | 2017-02-22 | 赫普泰雅治疗有限公司 | Muscarinic m1 receptor agonists |
| DK2897948T3 (en) | 2012-09-18 | 2016-12-05 | Heptares Therapeutics Ltd | BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS |
| EP2953940B1 (en) | 2013-02-07 | 2018-08-22 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists |
| EP3406609A1 (en) | 2014-02-06 | 2018-11-28 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| PL3265459T3 (en) | 2015-02-13 | 2019-09-30 | Suven Life Sciences Limited | Amide compounds as 5-ht4 receptor agonists |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201709652D0 (en) | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| TW201922758A (en) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | Enamines and diastereo-selective reduction of enamines |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202103211D0 (en) | 2021-03-08 | 2021-04-21 | Heptares Therapeutics Ltd | Pharmaceutical compounds for use in therapy |
-
2012
- 2012-11-16 CN CN201280066372.3A patent/CN104039321B/en active Active
- 2012-11-16 HU HUE12794751A patent/HUE033114T2/en unknown
- 2012-11-16 JP JP2014541757A patent/JP6083818B2/en active Active
- 2012-11-16 IN IN1075KON2014 patent/IN2014KN01075A/en unknown
- 2012-11-16 DK DK12794751.3T patent/DK2780015T3/en active
- 2012-11-16 EP EP12794751.3A patent/EP2780015B1/en active Active
- 2012-11-16 BR BR112014012056-0A patent/BR112014012056B1/en active IP Right Grant
- 2012-11-16 PL PL12794751T patent/PL2780015T3/en unknown
- 2012-11-16 ES ES12794751.3T patent/ES2619829T3/en active Active
- 2012-11-16 WO PCT/GB2012/052857 patent/WO2013072705A1/en active Application Filing
- 2012-11-16 CA CA2856076A patent/CA2856076C/en active Active
- 2012-11-16 GB GB1410398.0A patent/GB2511685A/en not_active Withdrawn
- 2012-11-16 CN CN201710078042.0A patent/CN106831541B/en active Active
- 2012-11-16 SG SG11201402405QA patent/SG11201402405QA/en unknown
- 2012-11-16 AU AU2012338581A patent/AU2012338581B2/en active Active
- 2012-11-16 US US14/358,984 patent/US9187451B2/en active Active
- 2012-11-16 PT PT127947513T patent/PT2780015T/en unknown
-
2015
- 2015-03-06 HK HK15102310.2A patent/HK1201737A1/en unknown
- 2015-11-13 US US14/941,328 patent/US9573929B2/en active Active
-
2017
- 2017-01-19 JP JP2017007283A patent/JP6404374B2/en active Active
- 2017-02-17 US US15/436,224 patent/US9907805B2/en active Active
- 2017-03-06 AU AU2017201505A patent/AU2017201505B2/en active Active
-
2018
- 2018-02-01 US US15/886,249 patent/US10413553B2/en active Active
- 2018-09-28 AU AU2018236871A patent/AU2018236871B2/en active Active
-
2019
- 2019-09-04 US US16/560,529 patent/US10973832B2/en active Active
-
2021
- 2021-04-09 US US17/226,523 patent/US11793817B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1201737A1 (en) | Muscarinic m1 receptor agonists | |
| PT2794626T (en) | E-selectin antagonist compounds | |
| GB201213700D0 (en) | Receptor antagnists II | |
| EP2665707A4 (en) | Mineralocorticoid receptor antagonists | |
| HUE039607T2 (en) | Progesterone antagonists | |
| SG10201500486QA (en) | Probing device | |
| EP2712534A4 (en) | Probe | |
| PL2649068T3 (en) | Oxazolyl-methylether derivatives as alx receptor agonists | |
| EP2684915A4 (en) | Polyethylene-based structure | |
| HK1206760A1 (en) | Dr5 receptor agonist combinations dr5 | |
| GB201116131D0 (en) | Probe | |
| HK1205706A1 (en) | V1a receptor agonists v1a | |
| EP2765860A4 (en) | Mineralocorticoid receptor antagonists | |
| EP2697203A4 (en) | Mineralocorticoid receptor antagonists | |
| EP2765859A4 (en) | Mineralocorticoid receptor antagonists | |
| EP2566494A4 (en) | Cxcr4 receptor compounds | |
| HK1197183A1 (en) | Methods for increasing osteoblastic function | |
| EP2765858A4 (en) | Mineralocorticoid receptor antagonists | |
| EP2600887A4 (en) | Microcrystalline y receptor agonists | |
| EP2756374A4 (en) | Autobiographical interface | |
| GB201223053D0 (en) | Receptor | |
| GB201116152D0 (en) | Cannabinoid-2-receptor agonists | |
| GB201113354D0 (en) | Leptin receptor structure | |
| AU4553P (en) | WES04 Westringia fruticosa | |
| GB201116151D0 (en) | Cannabinoid-2-receptor agonists |